相关临床试验
144
28 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1361
进行中（未招募）
4
2.8%
已完成
82
56.9%
Enrolling By Invitation
8
5.6%
尚未招募
16
11.1%
招募中
19
13.2%
Unknown
14
9.7%
撤回
1
0.7%
暂无批准数据
- EU-funded researchers are using silk fibroin, a protein derived from silkworms, to build bioreactors that mimic bone marrow and produce platelets outside the human body. - The technology addresses a critical supply bottleneck, as donor platelets can be preserved for only about five days and require room-temperature storage. - A silk-based bioink now enables 3D-printing of bone marrow models that reduce cellular stress and DNA damage, improving drug testing and disease research. - Researchers report successful small animal tests and say clinical application is the next step, with a start-up (Silk4B) already commercializing the models.
- Solid Biosciences has received FDA IND and Health Canada CTA approval for SGT-501, a novel gene therapy designed to treat catecholaminergic polymorphic ventricular tachycardia (CPVT), a rare genetic heart condition that can cause sudden death. - SGT-501 represents the first potential therapy to address the underlying mechanisms of CPVT by delivering a functional copy of the CASQ2 gene to stabilize calcium regulation in heart muscle cells. - The company plans to initiate a Phase 1b clinical trial in the fourth quarter of 2025, marking a significant milestone for patients with this life-threatening condition that currently has no approved treatments. - CPVT affects approximately 1 in 10,000 individuals globally and is often triggered by physical activity or emotional stress, leading to dangerous arrhythmias in otherwise healthy hearts.
- Neuboron Medical Group has established China's first accelerator-based Boron Neutron Capture Therapy (BNCT) center, making China the second country globally to offer this advanced cancer treatment technology. - The company's NeuPEX Block-I system demonstrates superior performance metrics, including 11cm treatment depth and 40cm irradiation aperture, alongside innovative boron drugs with improved clinical characteristics. - Over three years of operation at Xiamen Humanity Hospital, the system has conducted more than 40 clinical trials and 50 irradiation treatments, validating its stability and reliability.
